Clinical Trials

46 enrolled

Other solid neoplasm

Solid Tumors

NCT07460180 2026-03-10

PROOV

55 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

57 enrolled

CNS

Glioma

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

60 enrolled

Breast Neoplasms

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase EARLY_PHASE1 Recruiting

78 enrolled

CNS

Glioblastoma

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

90 enrolled

Pancreatic Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

18 enrolled

BRCA1 Mutation

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

64 enrolled

Genitourinary

Prostatic Neoplasms

NCT05498272 2026-01-23

NePtune

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Phase 3 Recruiting

554 enrolled

Endometrial Neoplasms

NCT02813135 2026-01-16

ESMART

472 enrolled

Tumor-Agnostic

Neoplasms

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

880 enrolled

Ovarian Neoplasms

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

50 enrolled

Fallopian Tube Neoplasms

NCT05524935 2026-01-08

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

37 enrolled

Dermatologic

Uveal Melanoma

NCT04711824 2025-12-23

SOLARA

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04550104 2025-12-19

CONCORDE

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05568212 2025-12-01

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

176 enrolled

Non-small-cell Lung Cancer Patients

NCT05900895 2025-11-20

PHOEBE

6 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06130254 2025-10-14

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Other solid neoplasmThoracic

52 enrolled

Advanced Solid Tumor

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

20 enrolled

Pancreatic Neoplasms

NCT07151911 2025-09-03

ROYAL

Recruiting

100 enrolled

Breast Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

20 enrolled

Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

119 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05623319 2025-06-24

THOR

60 enrolled

SCLC,Extensive Stage

NCT05870423 2025-06-05

PRRT-PARPi

24 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04515836 2025-05-06

Olaparib in Patients With HRD Malignant Mesothelioma

Other solid neoplasmThoracic

56 enrolled

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

Phase EARLY_PHASE1 Recruiting

10 enrolled

CNS

Glioblastoma, Recurrence

NCT05536128 2025-04-17

Post-CDK

64 enrolled

Advanced Breast Cancer

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT03786796 2025-03-13

ORCHID

20 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05222971 2025-01-28

OPTIMUM

62 enrolled

Biliary Tract Neoplasms

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Endometrial Neoplasms

NCT06607692 2024-10-21

LUPARPED

25 enrolled

CNSEndocrineNET

Adrenal Gland Neoplasms, Medulloblastoma, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03991832 2024-07-18

SOLID

58 enrolled

CNSGastrointestinal

Glioma, Cholangiocarcinoma

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

45 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT06078787 2024-05-06

PALBOLA

16 enrolled

Pancreatic Neoplasms

NCT06298084 2024-03-29

ICARUSBREAST02

152 enrolled

Breast Cancer Metastatic

NCT04825990 2022-04-07

POINT